22 Jul

#NewTrialAnnouncement

PharmaSols is delighted to be working with UNITY Biotechnology, Inc. (UNITY) on their latest ophthalmologic study UBX1325-02, across multiple sites in Australia and New Zealand.

The study is a Phase 2a, Prospective, Multicentre, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Oedema (DME).

UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with DME, nAMD, and DR.

UNITY and PharmaSols look forward to forging a strong on-going relationship. As UNITY expands its global footprint with clinical studies, they are very excited to include AU and NZ in this important effort.

Find out more https://lnkd.in/g_MXh9U

Other News

How To Avoid Costly Errors in Ethics and Regulatory Submissions

Ethics and Regulatory applications are a necessary complexity that can determine trial start-up timeframes or, in some cases, throw trial startup timelines immediately off-target if done incorrectly. Selecting who should be responsible for completing this application can also have a significant impact on the continuity of the trial.

Read more
Assured Continuity

Yesterday New Zealand was dealt a new challenge with one suspected case of the new Delta variant in the community. With the New Zealand government’s commitment to eradication of COVID-19 in the community, New Zealand has been placed in a lockdown for to a 7 day period. However we have proven our ability to work through the challenges of running a clinical trial through a pandemic.

Read more
RADIO NEW ZEALAND NATIONAL_Valneva New Study

Exciting for PharmaSols CRO and NZ to be involved in this international COVID-19 vaccine trial.

Read more